Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

被引：0
作者：
Goto, Y. [1 ]
Yamamoto, N. [2 ]
Masters, E. [3 ]
Kikkawa, H. [4 ]
Mardekian, J. [3 ]
Wiltshire, R. [5 ]
Togo, K. [4 ]
Ma, H. [6 ]
Ohe, Y. [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Wakayama Med Univ, Dept Internal Med, Wakayama, Japan
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Japan Inc, Tokyo, Japan
[5] Pfizer Inc, Tadworth, England
[6] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK-positive NSCLC; treatment sequencing; tyrosine kinase inhibitor;
D O I：
10.1016/j.jtho.2018.08.1590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-30
引用
收藏
页码：S878 / S879
页数：2
相关论文
共 50 条
  • [31] Capmatinib for the treatment of non-small cell lung cancer
    Vansteenkiste, Johan Filip
    Van de Kerkhove, Charlotte
    Wauters, Els
    Van Mol, Pierre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 659 - 671
  • [32] Real-world treatment outcomes with brigatinib in patients with pretreated ALK plus metastatic non-small cell lung cancer
    Popat, Sanjay
    Brustugun, Odd Terje
    Cadranel, Jacques
    Felip, Enriqueta
    Garassino, Marina Chiara
    Griesinger, Frank
    Helland, Aslaug
    Hochmair, Maximilian
    Perol, Maurice
    Bent-Ennakhil, Nawal
    Kruhl, Christian
    Novello, Silvia
    LUNG CANCER, 2021, 157 : 9 - 16
  • [33] Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
    Lee, Po-Hsin
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chang, Gee-Chen
    ANTI-CANCER DRUGS, 2021, 32 (10) : 1099 - 1104
  • [34] Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer
    Riley, D.
    Kaur, N.
    Baglione, A.
    Hall, R.
    Barnes, L.
    Gentzler, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1092 - S1092
  • [35] Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
    Fraser, Madison
    Seetharamu, Nagashree
    Diamond, Matthew
    Lee, Chung-Shien
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 1233 - 1243
  • [36] Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer
    Katayama, Ryohei
    PHARMACOLOGY & THERAPEUTICS, 2017, 177 : 1 - 8
  • [37] Anaplastic Lymphoma Kinase (ALK)-positive Tumors Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma
    Gupta, Rohan
    Amanam, Idoroenyi
    Rahmanuddin, Syed
    Mambetsariev, Isa
    Wang, Yingyu
    Huang, Charity
    Reckamp, Karen
    Vora, Lalit
    Salgia, Ravi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (04): : 337 - 344
  • [38] Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
    Scagliotti, Giorgio
    Govindan, Ramaswamy
    ONCOLOGIST, 2010, 15 (05) : 436 - 446
  • [39] Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
    Li, Junlong
    Knoll, Stefanie
    Bocharova, Iryna
    Tang, Wenxi
    Signorovitch, James
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (01) : 105 - 111
  • [40] Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
    Ohtaki, Yoichi
    Shimizu, Kimihiro
    Suzuki, Hiroyuki
    Suzuki, Kenji
    Tsuboi, Masahiro
    Mitsudomi, Tetsuya
    Takao, Motoshi
    Murakawa, Tomohiro
    Ito, Hiroyuki
    Yoshimura, Kenichi
    Okada, Morihito
    Chida, Masayuki
    LUNG CANCER, 2021, 153 : 108 - 116
12345